| __timestamp | Bristol-Myers Squibb Company | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 3932000000 | 4932500000 |
| Thursday, January 1, 2015 | 3909000000 | 5037200000 |
| Friday, January 1, 2016 | 4946000000 | 5654900000 |
| Sunday, January 1, 2017 | 6066000000 | 6070200000 |
| Monday, January 1, 2018 | 6547000000 | 4681700000 |
| Tuesday, January 1, 2019 | 8078000000 | 4721200000 |
| Wednesday, January 1, 2020 | 11773000000 | 5483300000 |
| Friday, January 1, 2021 | 9940000000 | 7312800000 |
| Saturday, January 1, 2022 | 10137000000 | 6629800000 |
| Sunday, January 1, 2023 | 10693000000 | 7082200000 |
| Monday, January 1, 2024 | 11949000000 | 8418299999 |
Cracking the code
In the competitive landscape of the pharmaceutical industry, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Eli Lilly and Company and Bristol-Myers Squibb Company from 2014 to 2023. Over this period, Bristol-Myers Squibb demonstrated a significant increase in cost efficiency, with their cost of revenue growing by approximately 173%, from $3.9 billion in 2014 to $10.7 billion in 2023. In contrast, Eli Lilly's cost of revenue increased by about 44%, from $4.9 billion to $7.1 billion during the same period.
The data reveals that while both companies have seen growth, Bristol-Myers Squibb's cost of revenue has surged more dramatically, particularly between 2019 and 2020, where it jumped by 46%. This could indicate strategic investments or shifts in operational efficiency. Understanding these trends provides valuable insights into the financial strategies of these pharmaceutical giants.
Breaking Down Revenue Trends: Eli Lilly and Company vs Bristol-Myers Squibb Company
Eli Lilly and Company and Bristol-Myers Squibb Company: A Detailed Gross Profit Analysis
Cost of Revenue: Key Insights for Eli Lilly and Company and Grifols, S.A.
Analyzing Cost of Revenue: Eli Lilly and Company and Xencor, Inc.
Cost Insights: Breaking Down AstraZeneca PLC and Bristol-Myers Squibb Company's Expenses
Bristol-Myers Squibb Company vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Xenon Pharmaceuticals Inc.
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs Bausch Health Companies Inc.
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Cost of Revenue Comparison: Bristol-Myers Squibb Company vs Evotec SE
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs Viridian Therapeutics, Inc.